Skip to main content
COLLEGIUM PHARMACEUTICAL, INC logo

COLLEGIUM PHARMACEUTICAL, INC — Investor Relations & Filings

Ticker · COLL ISIN · US19459J1043 LEI · 54930049FXZMTLW8D496 US Manufacturing
Open in API
Filings indexed 821 across all filing types
Latest filing 2020-05-15 Director's Dealing
Country US United States of America
Listing US COLL

About COLLEGIUM PHARMACEUTICAL, INC

https://www.collegiumpharma.com/

Collegium Pharmaceutical, Inc. is a diversified biopharmaceutical company that develops and commercializes medicines for people with serious medical conditions. The company is focused on building a portfolio of differentiated medications. Its primary area of expertise is in pain management, where it develops products with abuse-deterrent properties designed to be safer alternatives for patients and the community.

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2020-05-15 English
PRIMARY DOCUMENT
Director's Dealing
2020-05-15 English
10-Q
Interim / Quarterly Report Q1 2020
2020-05-07 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 7, 2020, reporting the issuance of a press release announcing financial results for the quarterly period ended March 31, 2020. The text explicitly states that the press release is attached as an exhibit and is being furnished, not filed, under Item 2.02. The document itself does not contain the financial results or detailed financial statements but rather announces the release of such information. The length of the document is 3502 characters, which is relatively short and consistent with an announcement rather than a full report. According to the classification rules, this type of document is best classified as a Regulatory Filing (RNS) because it is a current report announcing financial results but does not contain the full financial data or detailed analysis typical of an Earnings Release (ER) or Interim Report (IR).
2020-05-07 English
SC 13G
Major Shareholding Notification
2020-04-22 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A filing, which is a definitive proxy statement or definitive additional materials related to a shareholder meeting. It includes information about the annual meeting of shareholders, proposals to be voted on, board recommendations, and instructions for voting. It does not contain financial statements or detailed financial results, but rather proxy solicitation materials. The presence of terms like 'Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934' and detailed voting instructions confirms this is a proxy solicitation document. Therefore, the correct classification is Proxy Solicitation & Information Statement (PSI). The document length (6462 characters) and content confirm it is not merely an announcement but actual proxy materials or additional proxy materials.
2020-04-09 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.